Regulatory Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC Pharmaceutical TechnologyThe EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories' Braftovi to treat mCRC with BRAFV600E mutations.OncologyRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology The EMA’s CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations. Oncology Read full story Post navigation Previous: All eyes on Revolution, bispecific antibodies and more at ASCO26Next: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
